Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial - 07/08/11
Reprint requests: Enzo Madonini, MD, Via Cicognara 6, 20129 Milan, Italy.Abstract |
Background |
Asthma control is now recognized as the main goal of asthma therapy. Guidelines recommend finding the lowest effective dose of inhaled corticosteroids in children with persistent asthma.
Objective |
The aim of this study was to investigate the efficacy of an allergen-specific immunotherapy with a high-dose hypoallergenic mite preparation (allergoid) as steroid-sparing agent in children with allergic asthma.
Methods |
Sixty-five children with asthma (Global Initiative for Asthma treatment levels II and III; 6-17 years old), after reaching asthma control with inhaled steroids during a 5-month baseline period, were randomized for subcutaneous mite allergoid immunotherapy (SCIT) plus fluticasone propionate (FP) or FP therapy alone for 2 years. During 2 subsequent 5-month winter periods, steroid therapy was adjusted according to predefined dose steps, determining and comparing the changes in FP dosages and the lowest FP dose sufficient to maintain asthma control. Immunologic and functional investigations were also carried out.
Results |
Children treated with house dust mite SCIT plus FP were able to significantly reduce the FP dose by more steps (P < .05), compared with the control group on FP alone. The mean daily dose in the immunotherapy group decreased from 330.3 μg in the baseline period to 151.5 μg after 2 treatment years, whereas in the control group the dose decreased from 290.6 μg to 206.3 μg. Compared with the control group, significant improvement was also observed in morning peak expiratory flow (P = .0315). Significantly increased levels of specific IgG1 (P = .0001) and IgG4 (P < .0001) were also observed.
Conclusion |
Adding a mite allergoid SCIT to pharmacologic treatment is an effective and safe strategy to reduce corticosteroid doses while maintaining disease control in children with mite-induced allergic asthma.
Le texte complet de cet article est disponible en PDF.Key words : Subcutaneous immunotherapy, allergoid, house dust mite, asthma control, children, hypoallergenic preparation, controlled trial, efficacy, safety, Dermatophagoides pteronyssinus
Abbreviations used : FP, GINA, ICS, PEF, SCIT, SIT, SLIT, SPT, TU
Plan
| Supported by Allergopharma Joachim Ganzer KG, Reinbek, Germany. |
|
| Disclosure of potential conflict of interest: S. Zielen has received research support from Allergopharma, MSD, and Bencard. P. Kardos has received research support from Boehringner Ingelheim and AstraZeneca, is on the QAB and Omalizumab Advisory Board for Novartis and the Mundipharma Advisory Board, and has given presentations for GlaxoSmithKline, Mundipharma, AstraZeneca, Novartis, Bionorica, Cefalon, and Janssen-Cilag. E. Madonini is a consultant for Allergopharma SPA. |
|
| Trial registration: Clinical Trials.gov identifier: NCT00263640. |
Vol 126 - N° 5
P. 942-949 - novembre 2010 Retour au numéro
Article précédent
- The Editors’ Choice
- Donald Y.M. Leung, Stanley J. Szefler, Associate Editors of the JACI
- Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: A random-sample population study
- Asger Sverrild, Celeste Porsbjerg, Simon Francis Thomsen, Vibeke Backer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?